+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07210515

Randomized, Triple-Blind Study of Intravenous Neridronate Versus Placebo for Treating Complex Regional Pain Syndrome Type 1

Led by Ambros Therapeutics, Inc. · Updated on 2026-10-29

270

Participants Needed

33

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a phase 3 multicenter, randomized, triple-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of intravenous neridronate AMBTX-01 in adults diagnosed with the warm subtype of Complex Regional Pain Syndrome Type 1 CRPS-1 confirmed by a positive triple phase bone scan. The study targets participants with symptoms onset within 6 months and aims to compare neridronate with placebo in treating this painful condition. Participants will receive either 400 mg of neridronate or a placebo, administered as a 2-hour intravenous infusion on Days 1, 4, 7, and 10. The trial spans approximately 18 weeks, including a screening period of 2 to 6 weeks, the treatment dosing over 10 days, and a post-treatment follow-up period lasting through Week 12 to monitor effects and safety. During the study, participants will undergo various assessments including pain intensity measurements, CRPS severity scoring, health surveys, range of motion tests, and monitoring of rescue medication use at multiple timepoints from Day 10 up to Week 12. Data collection includes patient and clinician global impressions, sleep interference scales, and physical function evaluations. Researchers will also track safety and tolerability throughout the trial.

CONDITIONS

Brief Title

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)

Research Team

M

Medical Affairs

A

Ambros Therapeutics, Inc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here